Belzutifan for teenagers with advanced or spreading solid tumors
Tests belzutifan in adolescents with advanced solid tumors, including pheochromocytoma and paraganglioma.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Seoul, South KoreaSee the 2 sitesAlso in 7 other countries, 17 sites
- Trial code
- NCT07700758
- EU 2025-524515-37-00
- U1111-1330-9370
- Registry title
- A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Started
- 13 Oct 2026
- Expected to end
- 2 Jan 2034
- Type of study
- Interventional
- Treatments tested
- Belzutifan
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adolescents with certain solid tumors: pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumor, or localized tumors linked to von Hippel-Lindau disease. It tests the safety of belzutifan.
- Age
- 12 Years to 17 Years
- Sex
- All sexes can join.
- Disease stage
- Locally advanced, unresectable or metastatic pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumor, or localized tumors linked to von Hippel-Lindau disease. The disease must be measurable per RECIST 1.1.
- Earlier treatment
- People who had earlier treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan, cannot join.
Main reasons for not taking part
- Pulse oximeter reading <92% at rest, or need for supplemental oxygen
- Clinically significant cardiac disease, uncontrolled cardiac condition or congenital long QT syndrome
- History of human immunodeficiency virus infection
- Prior treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan
- Active infection requiring systemic therapy
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has a diagnosis of one of the following: locally advanced, unresectable, or metastatic pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumors, or localized tumors associated with von Hippel-Lindau disease
- Has measurable disease per RECIST 1.1
Who cannot take part
- Has received prior treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan
- Has had an allogenic tissue/solid organ transplant
- Has a history of human immunodeficiency virus infection
- Has a history of autologous stem cell transplant within 6 months of start of study intervention
- Has known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has an active infection requiring systemic therapy
- Has clinically significant cardiac disease or electrocardiogram indicating uncontrolled cardiac condition or has congenital long QT syndrome
- The main exclusion criteria include but are not limited to the following:
- Has a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- Has known active central nervous system metastases and/or carcinomatous meningitis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Where in South Korea
Also in 7 other countries, 17 sites
- Asan Medical Center-Pediatrics - Pedicatric Oncology (Site 5973)Seoul, South KoreaContact: Study CoordinatorTaking people
- Seoul National University Hospital-Pediatrics (Site 5972)Seoul, South KoreaContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease-associated localized tumors cohorts:
Read full original descriptionShow less
* PPGL are rare cancers that start in cells that make hormones in the adrenal glands * wtGIST is a less common type of cancer that starts in the digestive tract. Wild type means it does not have certain gene mutations (changes) * VHL disease-associated localized tumors are rare tumors caused by a certain gene mutation that may be passed down from parents to children * Locally advanced means the cancer has spread into nearby tissue * Unresectable means the cancer cannot be removed by surgery * Metastatic means the cancer has spread to other parts of the body
The goal of the study is to learn about the safety of belzutifan and if people tolerate it.
The group in the trial
- BelzutifanTreatment being tested
Participants will receive belzutifan 80 mg (body weight \<40 kg) or 120 mg (body weight ≥40 kg) orally once daily for approximately 2 years.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors
- Plain-language title
- Belzutifan for teenagers with advanced or spreading solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07700758, who can take part
- Record updated
- 10 November 2026